Drug Profile
Research programme: vaccines - Zosano Pharma
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Zosano Pharma
- Class Lyme disease vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Diphtheria; Hepatitis B; Lyme disease; Tetanus
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Cancer in USA (Transdermal, Patch)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Diphtheria in USA (Transdermal, Patch)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Transdermal, Patch)